Gilead Raises HCV Guidance Slightly, Still Mum On M&A
Gilead thinks 2017 HCV sales could reach as high as $9bn, still down from 2016, but higher than projected six months ago. Meanwhile, sales of TAF-based HIV regimens continue to grow and gain market share.
You may also be interested in...
Gilead projects roughly $200m in sales growth for its CAR-T product Yescarta, despite the drug’s modest $6m sequential growth during the fourth quarter. For 2019 overall sales, the company projects slight growth, if any.
Hemophilia and immuno-oncology will be in the spotlight as earnings season continues into February. Will Bristol be a buyer or an acquisition target? How will Sanofi fare with its new acquisitions? And how will Teva and GSK fare as they face generics for top brands?
Within weeks of its acquisition of Kite, Gilead is working to launch its first immuno-oncology drug, with a goal of training 70-90 US cancer centers. Q3 saw continued increase in HIV sales, decrease in HCV revenues.